SCHEMBL442434

SCHEMBL442434

O=C(O)[CH]Cc1ccccc1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAOB P27338 1/20 0.52
CES2 O00748 1/20 0.48
CES1 P23141 1/20 0.48
AKR1B1 P15121 1/20 0.48
CYP2C19 P33261 2/20 0.47
NPC1 O15118 2/20 0.47
RAB9A P51151 2/20 0.47
TOP1 P11387 1/20 0.46
CA1 P00915 1/20 0.45
CA2 P00918 1/20 0.45
ARG2 P78540 1/20 0.45
KEAP1 Q14145 1/20 0.44
ALDH1A1 P00352 2/20 0.44
LMNA P02545 1/20 0.44
CYP2D6 P10635 1/20 0.44
HCAR2 Q8TDS4 1/20 0.44
CYP1A2 P05177 1/20 0.43
CA12 O43570 1/20 0.42
CA9 Q16790 1/20 0.42
TSHR P16473 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8665145 0.81 MAOB (0.48) MAOBCES2CES1AKR1B1CYP2C19
SCHEMBL3244969 0.81 ALDH1A1 (0.48) MAOBCES2CES1AKR1B1CYP2C19
SCHEMBL8067640 0.81 CA2 (0.52) AKR1B1CA1CA2ALDH1A1HCAR2
SCHEMBL295277 0.81 MAOB (0.48) MAOBCES2CES1AKR1B1CYP2C19
SCHEMBL3244427 0.79 CES1 (0.54) MAOBCES2CES1AKR1B1CYP2C19
SCHEMBL3244713 0.79 TDP1 (0.52) MAOBCES2CES1AKR1B1CYP2C19
SCHEMBL27582991 0.78 MAOB (0.44) MAOBCES2CES1AKR1B1CYP2C19
SCHEMBL8467379 0.78 MAOB (0.44) MAOBCES2CES1AKR1B1CYP2C19
SCHEMBL27640145 0.78 MAOB (0.44) MAOBCES2CES1AKR1B1CYP2C19
SCHEMBL3408806 0.78 MAOB (0.44) MAOBCES2CES1AKR1B1CYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 345 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3334710-B1 COMPOSITIONS AND METHODS FOR TREATING AND PREVENTING NEURODEGENERATIVE DISORDERS ALZHEON INC (US) 2023-10-04 EP claimed
US-20230133465-A1 COMPOSITIONS AND METHODS FOR TREATING AND PREVENTING NEURODEGENERATIVE DISORDERS ALZHEON, INC. 2023-05-04 US claimed
CN-109963922-B Aldehyde scavenger and method for removing aldehyde 东曹株式会社 2022-09-23 CN claimed
US-10590070-B2 Compositions and methods for treating and preventing neurodegenerative disorders ALZHEON, INC. (US) 2020-03-17 US claimed
US-20200061225-A1 ALDEHYDE SCAVENGER AND METHOD FOR REMOVING ALDEHYDES TOSOH CORPORATION (JP) 2020-02-27 US claimed
EP-3564334-A1 ALDEHYDE SCAVENGER AND ALDEHYDE REMOVAL METHOD Tosoh Corporation (JP) 2019-11-06 EP claimed
EP-2897940-B1 HETEROCYCLIC COMPOUNDS, MEDICAMENTS CONTAINING SAID COMPOUNDS, USE THEREOF AND PROCESSES FOR THE PREPARATION THEREOF BOEHRINGER INGELHEIM INT (DE) 2019-05-01 EP claimed
EP-3334710-A1 COMPOSITIONS AND METHODS FOR TREATING AND PREVENTING NEURODEGENERATIVE DISORDERS Alzheon, Inc. (US) 2018-06-20 EP claimed
CN-108026049-A COMPOSITIONS AND METHODS FOR TREATING AND PREVENTING NEURODEGENERATIVE DISORDERS 阿尔泽恩股份有限公司 2018-05-11 CN claimed
WO-2017027582-A1 COMPOSITIONS AND METHODS FOR TREATING AND PREVENTING NEURODEGENERATIVE DISORDERS ALZHEON, INC. (US) 2017-02-16 WO claimed
US-5962529-A OSTEOPOROSIS; RHEUMATIC DISORDERS; ORAL DISEASES; ANTIULCER AGENTS; ANTITUMOR AGENTS; ANTIINFLAMMATORY AGENTS; SKIN DISORDERS BRITISH BIOTECH PHARMACEUTICALS LIMITED (GB) 1999-10-05 US claimed
EP-0766665-B1 METALLOPROTEINASE INHIBITORS BRITISH BIOTECH PHARM (GB) 1999-07-28 EP claimed
EP-0766665-A2 METALLOPROTEINASE INHIBITORS BRITISH BIOTECH PHARMACEUTICALS LIMITED (GB) 1997-04-09 EP claimed
EP-0766664-A2 METALLOPROTEINASE INHIBITORS BRITISH BIOTECH PHARMACEUTICALS LIMITED (GB) 1997-04-09 EP claimed
WO-1995035276-A1 METALLOPROTEINASE INHIBITORS BRITISH BIOTECH PHARMACEUTICALS LIMITED (GB) 1995-12-28 WO claimed
WO-1995035275-A1 METALLOPROTEINASE INHIBITORS BRITISH BIOTECH PHARMACEUTICALS LIMITED (GB) 1995-12-28 WO claimed
US-4950666-A INSECTS, ACARIDS, AND NEMATODES FMC CORPORATION (US) 1990-08-21 US claimed
US-4818749-A Carboxyalkyl dipeptides and medical use thereof in treating hypertension and congestive heart failure SCHERING CORPORATION (US) 1989-04-04 US claimed
US-4073892-A ANTITHROMBOGENIC MITSUBISHI CHEMICAL INDUSTRIES LIMITED (JA) 1978-02-14 US claimed
US-3933800-A O-SUBSTITUTED OXIMES, MICROBIOCIDES GRUPPO LEPETIT S.P.A. (IT) 1976-01-20 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230133465-A1 COMPOSITIONS AND METHODS FOR TREATING AND PREVENTING NEURODEGENERATIVE DISORDERS PSEN2, CLN6, PSEN1 MAOB 127/4885CES2 420/4885CES1 840/4885
US-10590070-B2 Compositions and methods for treating and preventing neurodegenerative disorders PSEN2, CLN6, PSEN1 MAOB 127/4885CES2 420/4885CES1 840/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.